Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis.
暂无分享,去创建一个
Lisa Wang | Levon M Khachigian | L. Khachigian | S. Badar | D. Morris | M. Pourgholami | Roger G Fahmy | S. Chu | Mohammad H Pourgholami | Samina Badar | Stephanie Wai Ling Chu | David Lawson Morris | R. Fahmy | Lisa Wang | R. G. Fahmy
[1] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[2] S. Harper,et al. Regulation of vascular permeability by vascular endothelial growth factors. , 2002, Vascular pharmacology.
[3] D. Ribatti,et al. Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 1999 .
[4] Lois E. H. Smith,et al. Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.
[5] D. Morris,et al. Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. , 2007, Biochemical pharmacology.
[6] Jack A Roth,et al. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] G. Krissansen,et al. Antisense HIF-1α prevents acquired tumor resistance to angiostatin gene therapy , 2010, Cancer Gene Therapy.
[8] G. Godlewski,et al. Poly(ADP‐ribose)polymerase inhibition decreases angiogenesis. , 2006, Biochemical and biophysical research communications.
[9] M. Poruchynsky,et al. Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole , 2010, BMC Cancer.
[10] Lisa I. Wang,et al. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis , 2005, Cancer Chemotherapy and Pharmacology.
[11] M. Links,et al. Inhibition of Cell Proliferation, Vascular Endothelial Growth Factor and Tumor Growth by Albendazole , 2009, Cancer investigation.
[12] Ettenson Ds,et al. Centrosomes, microtubules, and microfilaments in the reendothelialization and remodeling of double-sided in vitro wounds. , 1992 .
[13] Napoleone Ferrara,et al. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. , 2005, Biochemical and biophysical research communications.
[14] R. C. Parish,et al. Anthelmintic activity of albendazole against liver flukes, tapeworms, lung and gastrointestinal roundworms , 1976, Experientia.
[15] F. Piscione,et al. Endothelial α1‐adrenoceptors regulate neo‐angiogenesis , 2008 .
[16] Giovanni Mazzoni,et al. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice , 2008, Cancer Chemotherapy and Pharmacology.
[17] I. Herman,et al. Mechanisms of normal and tumor-derived angiogenesis. , 2002, American journal of physiology. Cell physiology.
[18] E. Lacey,et al. Structure-activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin, in vitro. , 1985, Biochemical pharmacology.
[19] K. Suzuma,et al. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. , 2006, The American journal of pathology.
[20] D. Morris,et al. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. , 2001, Cancer letters.
[21] Nicodemus Tedla,et al. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun , 2006, Nature Biotechnology.
[22] A. Ullrich,et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.
[23] Peter Carmeliet,et al. VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.
[24] M. Karkkainen,et al. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis , 2000, Oncogene.
[25] J. Horton. Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations , 2002, Current opinion in infectious diseases.
[26] Napoleone Ferrara,et al. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.
[27] M. De Brabander,et al. Influence of the anthelmintic mebendazole on microtubules and intracellular organelle movement in nematode intestinal cells. , 1975, American journal of veterinary research.
[28] G. Viale,et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] N. Awasthi,et al. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling , 2009, Laboratory Investigation.
[30] T. Gardner,et al. Retinal angiogenesis in development and disease , 2005, Nature.
[31] M. Meissner,et al. Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms. , 2008, The Journal of investigative dermatology.
[32] H. Dvorak,et al. Vascular permeability, vascular hyperpermeability and angiogenesis , 2008, Angiogenesis.
[33] Jack A Roth,et al. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. , 2002, Molecular cancer therapeutics.
[34] Lisa I. Wang,et al. Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice , 2006, Clinical Cancer Research.
[35] L. Liaudet,et al. Serveur Académique Lausannois SERVAL serval.unil.ch , 2022 .
[36] N. Hay,et al. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo , 2005, Nature Medicine.
[37] B. Lal,et al. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. , 2001, Microvascular research.